N-Boc-3-溴-4-氟苯胺 | 836619-77-3

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯胺系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-Boc-3-溴-4-氟苯胺
• 中文别名: N-BOC-3-溴-4-氟苯胺
• 英文名称: tert-butyl 3-bromo-4-fluorophenylcarbamate
• 英文别名: tert-butyl N-(3-bromo-4-fluorophenyl)carbamate；(3-bromo-4-fluoro-phenyl)-carbamic acid tert-butyl ester；N-Boc-3-bromo-4-fluoroaniline
• CAS: 836619-77-3
• 化学式: C₁₁H₁₃BrFNO₂
• mdl: MFCD11975628
• 分子量: 290.132
• InChiKey: XPHQSYXWFLVFDU-UHFFFAOYSA-N

物化性质

• 沸点：
  275.9±30.0 °C(Predicted)
• 密度：
  1.459±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P301+P310,P305+P351+P338,P361,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Boc-3-bromo-4-fluoroaniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H311: Toxic in contact with skin
H332: Harmful if inhaled
Causes skin irritation
H315:
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P361: Remove/Take off immediately all contaminated clothing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Boc-3-bromo-4-fluoroaniline
CAS number: 836619-77-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H13BrFNO2
Molecular weight: 290.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (N-Boc-3-bromo-4-fluoroaniline)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-3-溴-4-氟苯胺 在 甲醇 、 草酰氯 作用下， 反应 2.0h， 以57 mg的产率得到3-溴-4-氟苯胺
  参考文献：
  名称：

  使用草酰氯对 N-叔丁氧羰基 (N-Boc) 基团进行温和脱保护

  摘要：

  我们报告了一种温和的方法，通过在甲醇中使用草酰氯，从结构多样的一组化合物（包括脂肪族、芳香族和杂环底物）中选择性脱保护N -Boc 基团。反应在室温条件下进行 1-4 小时，产率高达 90%。这种温和的程序应用于一种混合的药用活性化合物 FC1，它是一种新型的 IDO1 和 DNA Pol γ 双重抑制剂。对于这种去保护策略，假设了涉及草酰氯的亲电特性的更广泛的机制。

  DOI：

  10.1039/d0ra04110f
• 作为产物：
  描述：

  3-溴-4-氟苯甲酸 、 叔丁醇 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 20.0h， 生成 N-Boc-3-溴-4-氟苯胺
  参考文献：
  名称：

  EP1650192

  摘要：

  公开号：

文献信息

• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• [EN] PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS PHÉNYL-HÉTÉROARYL AMINE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2012066065A1

  公开（公告）日：2012-05-24

  The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

  本发明提供了一种化合物，其化学式为（I）：及其药用可接受的盐、对映体、立体异构体、转型异构体、互变异构体、二对映异构体或混合物。还提供了使用化合物I的方法来治疗由CDK9介导的疾病或症状，以及包含这些化合物的药物组合物。
• [EN] HETEROARYL COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2011026917A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

  本发明提供了一种公式(I)的化合物：以及药用可接受的盐。还提供了一种使用公式I化合物治疗由CDK抑制剂介导的疾病或病症的方法。
• ANTI-CANCER PHOSPHONATE ANALOGS
  申请人：Boojamra Constantine G.

  公开号：US20100022467A1

  公开（公告）日：2010-01-28

  The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗癌化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• Heteroaryl Compounds as Kinase Inhibitors
  申请人：Pfister Keith B.

  公开号：US20120157433A1

  公开（公告）日：2012-06-21

  The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

  本发明提供了一种公式(I)的化合物及其药学上可接受的盐。同时提供了一种使用公式I的化合物治疗由CDK抑制剂介导的疾病或病况的方法。